Semaglutide vs Tirzepatide vs Retatrutide: Reta vs Tirz vs Sema — Blood Sugar, GIP & Weight Loss Compared
Three generations of GLP-1 weight loss peptides — compared across mechanism, clinical trial outcomes, dosing, and tolerability.
Proven long-term safety data, widest clinical experience
Superior weight loss vs semaglutide with comparable tolerability
Greatest weight loss in trials; glucagon component adds energy expenditure
Mechanism: How Each Generation Works
Each successive generation of GLP-1 agonist expands receptor coverage to amplify metabolic effects. These compounds were originally developed for type 2 diabetes management. They address insulin resistance and have become the leading pharmacological approach to obesity and metabolic syndrome. Each compound reduces appetite and slows gastric emptying to support weight management. Early studies with native GLP-1 established the receptor biology. Subsequent generations optimized half-life and receptor breadth. Each generation produces progressively greater weight loss. For those asking which is the best GLP-1 for weight loss, the answer depends on individual tolerance and access. See the Semaglutide vs Tirzepatide head-to-head, the Semaglutide Dosage Guide, and the GLP-1 Peptides guide.
Semaglutide (GLP-1 mono-agonist)
Appetite suppression + glucose controlActivates GLP-1 receptors in the pancreas (insulin secretion, glucagon suppression), hypothalamus (appetite suppression), and GI tract (gastric emptying delay). The result is reduced caloric intake through appetite suppression and improved glycemic control.
Tirzepatide (GLP-1 + GIP dual agonist)
Enhanced appetite suppression + adipose metabolismAdds GIP receptor agonism to GLP-1 activity. GIP receptors are expressed in adipose tissue and the CNS, and GIP agonism enhances insulin secretion in a glucose-dependent manner, improves adipose tissue metabolism, and may reduce GLP-1-induced nausea. The dual mechanism produces greater weight loss than either agonist alone.
Retatrutide (GLP-1 + GIP + Glucagon triple agonist)
Appetite suppression + increased energy expenditureAdds glucagon receptor agonism to the dual GLP-1/GIP mechanism. Glucagon increases hepatic glucose output and — critically — increases energy expenditure by stimulating thermogenesis and fatty acid oxidation. This means retatrutide not only reduces caloric intake (via GLP-1/GIP) but also increases calories burned (via glucagon), producing the highest weight loss of any GLP-1 class agent in trials.
What the cited studies used
One row per compound: the amount and schedule administered in a specific indexed study, who received it, and the paper. These are reports of what was done in that study, not recommendations, and several are animal or single-dose studies. Where no indexed human regimen exists we say so rather than print a number. Community "stacks" and cycle schedules are not reproduced on this site.
Research use only. Compound Review scores vendors on documentation — laboratory certificates, lot records, pricing and company identity. Nothing on this page is guidance on human or veterinary use, dosing or health outcomes.
| Compound | Regimen in the study | Population | Source |
|---|---|---|---|
| Semaglutide | 2.4 mg subcutaneous once weekly for 68 weeks (after dose escalation), plus lifestyle intervention | 1,961 adults with BMI ≥30 (or ≥27 with a weight-related condition), no diabetes — STEP 1 | PMID 33567185 Wilding et al., N Engl J Med 2021 |
| Tirzepatide | 5, 10 or 15 mg subcutaneous once weekly for 72 weeks, including a 20-week escalation | 2,539 adults with BMI ≥30 (or ≥27 with a complication), no diabetes — SURMOUNT-1 | PMID 35658024 Jastreboff et al., N Engl J Med 2022 |
| Retatrutide | 1, 4, 8 or 12 mg subcutaneous once weekly for 48 weeks (initial doses 2–4 mg in the higher arms) Phase 2; the phase 3 TRIUMPH programme had not reported at the time of writing. | Adults with BMI ≥30 (or 27–30 with a weight-related condition) — phase 2 | PMID 37366315 Jastreboff et al., N Engl J Med 2023 |
Research use only. Compound Review scores vendors on documentation — laboratory certificates, lot records, pricing and company identity. Nothing on this page is guidance on human or veterinary use, dosing or health outcomes.
Pathway Comparison Diagram
Semaglutide activates GLP-1R only (~15% weight loss); Tirzepatide adds GIPR (~22%); Retatrutide adds GcgR on top of both (~24%) — each additional receptor drives incremental energy expenditure.
Side-by-Side Comparison
| Category | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor Targets | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Weight Loss (Clinical) | ~15% at 68 wk | ~22% at 72 wk | ~24% at 48 wk |
| Key Trial | STEP 1 (NEJM 2021) | SURMOUNT-1 (NEJM 2022) | Phase 2 (NEJM 2023) |
| FDA Status | Approved (Ozempic/Wegovy) | Approved (Mounjaro/Zepbound) | Phase 3 trials |
| Starting Dose | 0.25 mg/week | 2.5 mg/week | 0.5 mg/week (Phase 2) |
| Max Dose | 2.4 mg/week | 15 mg/week | 12 mg/week (Phase 2) |
| Dosing Frequency | Once weekly | Once weekly | Once weekly |
| Half-life | ~7 days | ~5 days | ~6 days (est.) |
| GI Side Effects | Moderate | Moderate | Moderate–High |
| Cardiovascular Data | Extensive (SELECT trial) | Growing (SURPASS-CVOT) | Limited (Phase 2 only) |
| Muscle Preservation | Moderate loss | Moderate loss | Under investigation |
| Molecular Weight | 4,114 Da | 4,813 Da | ~4,900 Da |
Clinical Weight Loss Outcomes
Note on cross-trial comparisons: Direct head-to-head trials between all three compounds have not been completed. Weight loss percentages are from separate Phase 2/3 trials with different populations, durations, and protocols. Retatrutide's Phase 2 data (48 weeks) may not directly compare to semaglutide and tirzepatide's Phase 3 data (68–72 weeks). A longer retatrutide trial may produce higher figures.
Research Context: Which Compound for Which Goal?
Semaglutide has the longest clinical history of the three, with extensive cardiovascular outcome data (SELECT trial, 17,604 participants). For research contexts where long-term tolerability data is critical, semaglutide offers the most comprehensive evidence base.
Tirzepatide produces ~22% weight loss vs ~15% for semaglutide, with a comparable side effect profile. For research focused on the metabolic effects of dual GLP-1/GIP agonism, tirzepatide is the current gold standard among approved agents.
Retatrutide's triple agonism — particularly the glucagon component's effect on energy expenditure — represents a mechanistically distinct approach. Phase 2 data shows ~24% weight loss at 48 weeks. Research into the GLP-1/GIP/glucagon axis is an active area of investigation.
Source All Three GLP-1 Compounds at Purgo Labs
Purgo Labs carries research-grade Semaglutide, Tirzepatide, and Retatrutide with third-party COAs from accredited US labs. Use code HEALTH for 20% off.
Frequently Asked Questions
Which is stronger: semaglutide, tirzepatide, or retatrutide?
Based on Phase 3 clinical trial data, retatrutide produces the greatest weight loss (~24% at 48 weeks), followed by tirzepatide (~22% at 72 weeks), then semaglutide (~15% at 68 weeks). However, retatrutide is still in trials and not yet FDA-approved.
What is the difference between semaglutide and tirzepatide?
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1/GIP agonist — the addition of GIP agonism produces greater weight loss and metabolic improvements than GLP-1 alone.
What makes retatrutide different from tirzepatide?
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. The glucagon component increases energy expenditure and hepatic fat oxidation, contributing to its superior weight loss in Phase 2 trials.
Is retatrutide FDA-approved?
As of 2025, retatrutide (LY3437943) is in Phase 3 clinical trials. It is not yet FDA-approved for any indication. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are both FDA-approved.
Which GLP-1 drug has the fewest side effects?
Semaglutide generally has the most established tolerability profile given its longer clinical history. Tirzepatide and retatrutide have similar GI side effect profiles (nausea, vomiting, diarrhea), though retatrutide may have more pronounced effects due to glucagon agonism.
Can you switch from semaglutide to tirzepatide or retatrutide?
Switching between GLP-1 agonists is clinically practiced, though protocols vary. A washout period is not typically required given the overlapping mechanism. Dose titration should restart from the lowest dose when switching compounds.